13F Holdings
中文EN

CSTL CASTLE BIOSCIENCES INC

Services-Medical Laboratories · Nasdaq · SEC CIK 1447362 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.8%
TTM net income YoY-88.1%
TTM EPS YoY-72.7%
Revenue 3-yr CAGR25.2%
Net income 3-yr CAGR—

Margins

Gross margin77.1%
Operating margin-7.4%
Net margin-6.1%
FCF margin1.1%
EBITDA margin-4.4%

Returns

ROE-4.9%
ROA-4.0%
ROIC (approx.)-5.5%
Asset turnover0.66x

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.02x
Current ratio5.28x
Interest coverage-51.16x

Cash quality & payout

Operating cash flow / net income-1.73x
Accruals ratio-11.0%
Payout ratio—
Capex / revenue9.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$344.23M$332.07M$219.79M$137.04M$94.08M
Cost of revenue$71.03M$60.20M$44.98M$32.01M$15.82M
Gross profit$273.20M$271.86M$174.81M$105.03M$78.26M
R&D expense$51.85M$52.04M$53.62M$44.90M$29.65M
SG&A expense$229.32M$200.05M$180.15M$143.00M$86.74M
Operating income-$42.81M$8.67M-$67.98M-$72.86M-$40.08M
Interest expense$86,000$577,000$11,000$17,000$1,000
Income tax-$5.36M$3.32M$101,000-$1.77M-$8.72M
Net income-$24.16M$18.25M-$57.47M-$67.14M-$31.29M
EBITDA-$2.04M$24.67M-$55.65M-$62.31M-$36.67M
EPS (basic)-0.830.66-2.14-2.58-1.24
EPS (diluted)-0.830.62-2.14-2.58-1.24
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)28.99M29.25M26.80M26.05M25.14M
Balance sheet
Cash & equivalents$116.73M$119.71M$98.84M$122.95M$329.63M
Short-term investments$182.78M$173.42M$144.26M$135.68M$0
Receivables$43.38M$51.22M$38.30M$23.48M$17.28M
Inventory$10.25M$8.13M$7.94M$3.98M$2.02M
Current assets$361.10M$360.15M$295.63M$292.29M$353.74M
PP&E, net$97.44M$51.12M$25.43M$14.31M$9.50M
Goodwill$10.70M$10.70M$10.70M$10.70M$0
Intangibles$88.88M$95.54M$106.64M$115.66M$88.92M
Total assets$578.56M$531.24M$453.34M$447.33M$462.57M
Current liabilities$68.68M$49.39M$47.67M$36.13M$24.89M
Short-term debt$417,000$278,000$0——
Long-term debt$9.64M$9.74M$0——
Total debt$10.06M$10.02M$0——
Total liabilities$107.68M$75.40M$62.07M$48.18M$50.83M
Shareholders' equity$470.87M$455.83M$391.27M$399.15M$411.74M
Net debt-$106.67M-$109.69M-$98.84M——
Shares outstanding29.69M28.48M27.41M26.55M25.38M
Cash flow statement
Operating cash flow$64.35M$64.87M-$5.63M-$41.66M-$18.98M
Capital expenditure$36.02M$28.33M$13.62M$5.63M$3.48M
Free cash flow$28.33M$36.54M-$19.25M-$47.29M-$22.47M
Investing cash flow-$60.37M-$50.14M-$16.18M-$166.54M-$66.66M
Financing cash flow-$6.96M$6.14M-$2.30M$1.51M$5.42M
Depreciation & amortization$40.77M$16.00M$12.33M$10.54M$3.41M
Stock-based compensation$45.89M$50.32M$51.22M$36.32M$21.74M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.